BIOCEUTICALS ARZNEIMITTEL AG
BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties.
BIOCEUTICALS ARZNEIMITTEL AG
Industry:
Manufacturing Pharmaceutical
Address:
Bad Vilbel, Hessen, Germany
Country:
Germany
Status:
Active
More informations about "BIOCEUTICALS Arzneimittel AG"
BIOCEUTICALS Arzneimittel AG - Crunchbase
BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties. Lists Featuring …See details»
BIOCEUTICALS Arzneimittel AG, Bad Vilbel, Germany - North Data
BIOCEUTICALS Arzneimittel AG, Bad Vilbel, Germany, District Court of Frankfurt HRB 72513: Earnings, Revenue, Patents, Total assets, Network, Financial informationSee details»
BIOCEUTICALS Arzneimittel AG - Company Profile and News
BIOCEUTICALS Arzneimittel AG. BIOCEUTICALS Arzneimittel Aktiengesellschaft was founded in 2000. The Company's line of business includes providing commercial physical and biological …See details»
BIOCEUTICALS Arzneimittel AG - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BIOCEUTICALS Arzneimittel AG of Bad Vilbel, Hessen. Get the latest business insights from …See details»
Bioceuticals Arzneimittel - PitchBook
Bioceuticals Arzneimittel is headquartered in Bad Vilbel, Germany. What is the size of Bioceuticals Arzneimittel? Bioceuticals Arzneimittel has 50 total employees. What industry is …See details»
STADA becomes Majority Shareholder of BIOCEUTICALS …
Aug 6, 2018 BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties. …See details»
BIOCEUTICALS Arzneimittel AG acquired by STADA Arzneimittel …
Aug 6, 2018 STADA Arzneimittel AG acquires BIOCEUTICALS Arzneimittel AG on 2018-08-06 for an undisclosed amountSee details»
BIOCEUTICALS Arzneimittel AG - Drug pipelines, Patents, Clinical …
Last update 19 Sep 2024. BIOCEUTICALS Arzneimittel AG. Subsidiary Company |See details»
BIOCEUTICALS Arzneimittel AG - Crunchbase
BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin.See details»
Company History - STADA
STADA is able to push ahead with the strategic portfolio expansion in important areas: repurchase of the rights to the sunscreen Ladival; acquisition of the EMEA rights to the worldwide anti …See details»
Hospira, STADA Arzneimittel AG And BIOCEUTICALS Enter Into
Nov 20, 2006 Initiated by STADA and located in Bad Vilbel, Germany, BIOCEUTICALS Arzneimittel AG is focused on the development of biosimilar products. BIOCEUTICALS is …See details»
Our history in biosimilars
STADA becomes majority shareholder of BIOCEUTICALS Arzneimittel AG, which creates an excellent basis for growth in biosimilars. 2019. 2019. STADA becomes shareholder of Xbrane …See details»
STADA Becomes Majority Shareholder Of BIOCEUTICALS …
BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties. The biosimilar …See details»
BIOCEUTICALS ARZNEIMITTEL AG innovation strategy - GoodIP
BIOCEUTICALS ARZNEIMITTEL AG has a total of 27 patent applications. Its first patent ever was published in 2002. It filed its patents most often in EPO (European Patent Office), Germany …See details»
FDA approves biologics facility to supply key medicine to patients …
Nov 8, 2023 A joint venture between STADA’s Bioceuticals Arzneimittel AG subsidiary and Nordmark Pharma GmbH, Norbitec is located on Nordmark’s campus in Uetersen, near …See details»
STADA strengthens oncology offering by launching bevacizumab
Mar 30, 2021 STADA has been engaged in bringing biosimilars to patients and healthcare professionals since founding the Bioceuticals Arzneimittel AG in 2000. Thereby, STADA …See details»
STADA becomes Majority Shareholder of BIOCEUTICALS …
Aug 6, 2018 STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG. 06/08/2018 ; Investor News; CEO Claudio Albrecht: “Excellent basis for further strong growth …See details»
STADA Strengthens Oncology Offering By Launching Bevacizumab …
STADA has been engaged in bringing biosimilars to patients and healthcare professionals since founding the Bioceuticals Arzneimittel AG in 2000. Thereby, STADA contributes to the cost …See details»
Biosimilars manufacturing facilities approved by EU and US
Jun 6, 2023 Norbitec is a joint venture between STADA’s Bioceuticals Arzneimittel AG subsidiary and Nordmark Pharma GmbH, Norbitec is located on Nordmark’s campus in …See details»
SIMPLY OYAVAS | Oyavas
VEGF, vascular endothelial growth factor *Avastin® †Not all treatment schedules within each cancer type are approved due to patent protection ‡STADA founded Bioceuticals Arzneimittel …See details»